Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethanol-enoxaparin lock for prevention of central line-associated bloodstream infection
IRCT20220618055207N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of ethanol and enoxaparin in central line-associated bloodstream infection (CLABSI) and catheter-related thrombosis (CRT) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Occurrence of catheter-related bloodstream infection, Catheter colonization and 1 more. Started Apr 2024; status: completed.
02
Drugs
ethanolenoxaparin
03
Conditions
central line-associated bloodstream infection (CLABSI)catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on IRCT20220618055207N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220618055207N2.